Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia

Monika Brüggemann(University Hospital Schleswig-Holstein), Michael Kneba(Universitäts Hautklinik Kiel), Urban Scheuring(AstraZeneca (United Kingdom)), J Droese(Universitäts Hautklinik Kiel), Nicola Gökbuget(Goethe University Frankfurt), Thorsten Raff(Goethe University Frankfurt), Matthias Ritgen(Goethe University Frankfurt), Dieter Hoelzer(Endokrinologikum), Makoto Nakao(Kinjo Gakuin University), Thomas Flohr(Goethe University Frankfurt), Claus R. Bartram(Goethe University Frankfurt), Eckhard Thiel(Franklin University), Silke Lüschen(Goethe University Frankfurt), Christiane Pott(University Hospital Schleswig-Holstein), Heinz‐August Horst(Goethe University Frankfurt)
Blood
September 30, 2005
10.1182/blood-2005-07-2708
Cited by 537

Related Papers

Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
|New England Journal of Medicine|2002|3.3k
Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 Concerted Action BMH4-CT98-3936
|Leukemia|2003|3k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.7k
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial
|The Lancet|2019|2.6k
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
|The Lancet Oncology|2014|1.3k